Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of Teclistamab (JNJ-64007957) in Japanese Patients with Relapsed or Refractory Multiple Myeloma
jRCT2061200050Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of teclistamab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events (Phase 1), Number of Participants with Serious Adverse Events (Phase 1) and 2 more. Started Feb 2021; status: active, not recruiting.
02
Drugs
teclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2061200050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061200050.